Advertisement Mylan acquires Watson's 50% interest in Somerset Pharmaceuticals - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Mylan acquires Watson’s 50% interest in Somerset Pharmaceuticals

Mylan and Watson Pharmaceuticals have announced that Mylan has acquired Watson's 50% interest in the Somerset Pharmaceuticals joint venture.

Somerset, a proprietary research and development company located in Tampa, Florida, was formed in 1986, and since 1988, has been owned jointly by both Mylan and Watson.

Somerset developed Emsam, a transdermal patch for the treatment of major depressive disorder, currently marketed in the US by Bristol-Myers Squibb. Somerset will become a wholly-owned subsidiary of Mylan.